Inhibition of 17β-estradiol activation by CYP1A1: Genotype- and regioselective inhibition by St. John's Wort and several natural polyphenols

Biochimica et Biophysica Acta - Proteins and Proteomics

Volumn 1814, Issue 1, 2011, Pages 168-174

  Schwarz, Dieter ^a,b   Kisselev, Pyotr ^a,d   Schunck, Wolf Hagen ^c   Roots, Ivar ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Max Delbrueck Centre for Molecular Medicine ^*  (Germany)

^c MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^d INSTITUTE OF BIOORGANIC CHEMISTRY   (Belarus)

Author keywords

CYP1A1; Estradiol; Inhibition; Metabolic activation; Polymorphism

Indexed keywords

CAFFEIC ACID; CHLOROGENIC ACID; CYTOCHROME P450 1A1; ENZYME VARIANT; EPIGALLOCATECHIN GALLATE; ESTRADIOL; HYPERICIN; HYPERICUM PERFORATUM EXTRACT; KAEMPFEROL; MYRICETIN; POLYPHENOL; PSEUDOHYPERICIN; QUERCETIN; RESVERATROL; RUTOSIDE; STILBENE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; GENOTYPE; IC 50; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEROID HYDROXYLATION; WILD TYPE;

AMINO ACID SUBSTITUTION; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOCATALYSIS; CYTOCHROME P-450 CYP1A1; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTRADIOL; FLAVONOIDS; FLAVONOLS; GENOTYPE; HUMANS; HYDROXYLATION; HYPERICUM; PERYLENE; PHENOLS; PLANT EXTRACTS; QUERCETIN; RECOMBINANT PROTEINS; STEREOISOMERISM; STILBENES; SUBSTRATE SPECIFICITY;

HYPERICUM PERFORATUM;

EID: 78649446078     PISSN: 15709639     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbapap.2010.09.014     Document Type: Article

References (45)

1. P. Anzenbacher, and E. Anzenbacherova Cytochrome P450 and metabolism of xenobiotics Cell. Mol. Life Sci. 58 2001 737 747
2. J.H. Lin, and A.Y. Lu Interindividual variability and induction of cytochrome P450 enzymes Annu. Rev. Pharmacol. Toxicol. 41 2001 535 567
3. A.J. Lee, M.X. Cai, P.E. Thomas, A.H. Conney, and B.T. Zhu Characterization of the oxidative metabolites of 17β-estradiol and estrone formed by 15 selectively expressed human cytochrome P450 isoforms Endocrinology 144 2003 3382 3398
4. E. Cavalieri, K. Frenkel, and J.G. Liehr Chapter 4: estrogens as endogenous genotoxic agents-DNA adducts and mutations J. Natl. Cancer Inst. Monogr. 27 2000 75 93
5. I.H. Hanna, S. Dawling, F.P. Guengerich, and F.F. Parl Cytochrome P450 1B1 (CYP1B1) pharmacogenetics: association of polymorphisms with functional differences in estrogen hydroxylation activity Cancer Res. 60 2000 3440 3444
6. J.G. Liehr, and D. Roy Free radical generation by redox cycling of estrogens Free Radical Biol. Med. 8 1990 415 423
7. B.T. Zhu Catechol-O-methyltransferase (COMT)-mediated methylation metabolism of endogenous bioactive catechols and modulation by endobiotics and xenobiotics: importance in pathophysiology and pathogenesis Curr. Drug Metab. 3 2002 321 349
8. B.T. Zhu, and A.H. Conney Functional role of estrogen metabolism in target cells: review and perspectives Carcinogenesis 19 1998 1 27
9. R.K. Dubey, D.G. Gillespie, P.J. Keller, B. Imthurn, L.C. Zacharia, and E.K. Jackson Role of methoxyestradiols in the growth inhibitory effects of estradiol on human glomerular mesangial cells Hypertension 39 part2 2002 418 424
10. L.C. Zacharia, J.A. Gogos, and M. Karayiorgou Methoxyestradiols mediate the antimitogenic effects of 17β-estradiol. Direct evidence from catechol-O-methyltransferase-knockout mice Circulation 108 2003 2974 2978
11. N.J. Lakhani, M.A. Sarkar, J. Venitz, and W.D. Figg 2-Methoxyestradiol, a promising anticancer agent Pharmacotherapy 23 2003 165 172
12. M. Cizek, U. Iwaniec, and M. Goblirsch 2-Methoxyestradiol suppresses osteolytic breast cancer tumor progession in vivo Cancer Res. 67 2007 10106 10111
13. S. Dawling, N. Roodi, and F.F. Parl Methoxyestrogens exert feedback inhibition on cytochrome P450 1A1 and 1B1 Cancer Res. 63 2003 3127 3132
14. C.S. Huang, H.D. Chern, K.J. Chang, C.W. Cheng, S.M. Hsu, and C.Y. Shen Breast cancer risk associated with genotype polymorphism of the estrogen-metabolizing genes CYP17, CYP1A1, and COMT: a multigenic study on cancer susceptibility Cancer Res. 59 1999 4870 4875
15. P.F. Firozi, M.L. Bondy, and A.A. Sahin Aromatic DNA adducts and polymorphisms of CYP1A1, NAT2, and GSTM1 in breast cancer Carcinogenesis 23 2002 301 306
16. M. Murata, M. Watanabe, and Y. Yamanaka Genetic polymorphisms in cytochrome P450 (CYP) 1A1, CYP1A2, CYP2E1, glutathione s-transferase (GST) M1 and GSTT1 and susceptibility to prostate cancer in the Japanese population Cancer Lett. 165 2001 171 177
17. K. Suzuki, H. Matsui, and H. Nakazato Association of the genetic polymorphism in cytochrome P450 (CYP) 1A1 with risk of familial prostate cancer in a Japanese population: a case-control study Cancer Lett. 195 2003 177 183 (Pubitemid 36588967)
18. D. Aktas, I. Guney, M. Alikasifoglu, K. Yuce, E. Tuncbilek, and A. Ayhan CYP1A1 gene polymorphism and risk of epithelial ovarian neoplasm Gynecol. Oncol. 86 2002 124 128
19. K.B. Moysich, P.G. Shields, and J.L. Freudenheim Polychlorinated biphenyls, cytochrome P4501A1 polymorphism, and postmenopausal breast cancer risk Cancer Epidemiol. Biomarkers Prev. 8 1999 41 44
20. P. Kisselev, W.H. Schunck, I. Roots, and D. Schwarz Association of CYP1A1 polymorphisms with differential metabolic activation of 17β-estradiol and estrone Cancer Res. 65 2005 2972 2978
21. V. Butterweck Mechanism of action of St. John's Wort in depression: what is known? CNS Drugs 17 2003 539 562
22. A. Johne, I. Mai, and S. Bauer Übersicht zu Interaktionsstudien mit Johanniskraut V.D. Schulz, N. Rietbrock, I. Roots, D. Loew, Phytopharmaka VII 2001 Steinkopf Verlag Darmstadt 149 161
23. R.S. Obach Inhibition of human cytochrome P450 enzymes by constituents of St. John's Wort, an herbal preparation used in the treatment of depression J. Pharmacol. Exp. Ther. 294 2000 88 95
24. F. Borrelli, and A. Izzo Herb-drug interactions with St John's Wort (Hypericum perforatum): an update on clinical observations AAPS J. 11 2009 710 727
25. A. Nahrstedt, and V. Butterweck Biologically active and other chemical constituents of the herb Hypericum perforatum L. Pharmacopsychiatry 30 1997 129 134
26. A. Chernogolov, J. Behlke, W.H. Schunck, I. Roots, and D. Schwarz Human CYP1A1 allelic variants: baculovirus expression and purification, hydrodynamic, spectral and catalytical properties and their potency in the formation of all-trans-retinoic acid Protein Expr. Purif. 28 2003 259 269
27. D. Schwarz, P. Kisselev, W.H. Schunck, A. Chernogolov, W. Boidol, I. Cascorbi, and I. Roots Allelic variants of human cytochrome P4501A1 (CYP1A1): effect of T461N and I462V substitution on steropid hydroxylase specificity Pharmacogenetics 10 2000 519 530
28. S. Tamura, K.R. Korzekwa, S. Kimura, H.V. Gelboin, and F.J. Gonzalez Baculovirus-mediated expression and functional characterization of human NADPH-P450 oxidoreductase Arch. Biochem. Biophys. 293 1992 219 223
29. D. Schwarz, P. Kisselev, and S.S. Ericksson Arachidonic and eicosapentaenoic acid metabolism by human CYP1A1: highly stereoselective formation of 17(R), 18(S)-epoxyeicosatetraenoic acid Biochem. Pharmacol. 67 2004 1445 1457
30. T. Omura, and R. Sato The carbon monoxide-binding pigment of liver microsomes J. Biol. Chem. 239 1964 2370 2378
31. Y. Yasukochi, and B.S.S. Masters Some properties of a detergent-solubilized NADPH- cytochrome c (cytochrome P-450) reductase purified by biospecific affinity chromatography J. Biol. Chem. 251 1976 5337 5344
32. D. Schwarz, P. Kisselev, and I. Roots CYP1A1 genotype-selective inhibition of benzo[a]pyrene activation by quercetin Eur. J. Cancer 41 2005 151 158
33. + 1 J. Pharmacol. Exp. Ther. 290 1999 1363 1368
34. V. Butterweck, G. Jurgenliemk, and A. Nahrstedt Flavonoids from Hypericum perforatum show antidepressant activity in the forced swimming test Planta Med. 66 2000 3 6
35. M. Nöldner, and K. Schötz Rutin is essential for the antidepressant activity of Hypericum perforatum extracts in the forced swimming test Planta Med. 68 2002 577 580
36. D. Schwarz, P. Kisselev, and I. Roots St. John's Wort extracts and some their constituents potently inhibit ultimate carcinogen formation from benzo[a]pyrene-7, 8-dihydrodiol by human CYP1A1 Cancer Res. 63 2003 8062 8068
37. X. Ding, and L.S. Kaminsky Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts Annu. Rev. Pharmacol. Toxicol. 43 2003 149 173
38. A. Johne, J. Schmider, and J. Brockmöller Decreased plasma levels of amitriptyline and its metabolites on comedication with an extract from St. John's Wort (Hypericum perforatum) J. Clin. Psychopharmacol. 22 2002 46 54
39. G. Kavie, Y. Mazur, and D. Lavie The chemical biological properties of hypericin-a compound with a broad spectrum of biological activities Med. Res. Rev. 15 1995 111 119
40. X. Meng, P. Maliakal, and H. Lu Urinary and plasma levels of resveratrol and quercetin in humans, mice, and rats after ingestion of pure compounds and grape juice J. Agric. Food Chem. 52 2004 935 942
41. P.C.H. Hollman, and M.B. Katan Bioavailability and health effects of dietary flavonoids in man Arch. Toxicol. 20 1998 237 240
42. Z. Chen, Y. Hurh, and H. Nah Resveratrol inhibits TCDD-induced expression of CYP1A1 and CYP1B1 and catechol estrogen-mediated oxidative DNA damage in cultured human mammary epithelial cell Carcinogenesis 10 2004 2005 2013
43. S. McCann, J. Wactawski-Ewende, and K. Kufel Changes in 2-hydroxyestrone and 16alpha-hydroxyestrone metabolism with flaxseed consumption: modification by COMT and CYP1B1 genotype Canc. Epidem. Biomark. Prev. 16 2007 256 262
44. P.A. Gaspar, M.H. Hutz, and F.M. Salzano Polymorphisms of CYP1A1, CYP2E1, GSTM1, GSTT1, and TP53 genes in Amerindians Am. J. Phys. Anthropol. 119 2002 249 256
45. H. Ahsan, and A.G. Rundle Measures of genotype versus gene products: promise and pitfalls in cancer prevention Carcinogenesis 24 2003 1429 1434